Reviewed by Michael Gill, B. Sc.
9 Plexiform Neurofibroma Clinical Trials Near Me
Top Hospitals for Plexiform Neurofibroma Clinical Trials
Image of Children's National Medical Center in District of Columbia.
Children's National Medical Center
Washington
4Active Trials
7All Time Trials for Plexiform Neurofibroma
2002First Plexiform Neurofibroma Trial
Image of National Institutes of Health Clinical Center in Maryland.
National Institutes of Health Clinical Center
Bethesda
4Active Trials
9All Time Trials for Plexiform Neurofibroma
2008First Plexiform Neurofibroma Trial
Top Cities for Plexiform Neurofibroma Clinical Trials
Image of Bethesda in Maryland.
Bethesda
9Active Trials
National Institutes of Health Clinical CenterTop Active Site
Plexiform Neurofibroma Clinical Trials by Phase of Trial
Phase 1 Plexiform Neurofibroma Clinical Trials
2Active Plexiform Neurofibroma Clinical Trials
2Number of Unique Treatments
5Number of Active Locations
Plexiform Neurofibroma Clinical Trials by Age Group
Most Recent Plexiform Neurofibroma Clinical Trials
Top Treatments for Plexiform Neurofibroma Clinical Trials
Treatment Name
Active Plexiform Neurofibroma Clinical Trials
All Time Trials for Plexiform Neurofibroma
First Recorded Plexiform Neurofibroma Trial
Selumetinib
3
5
2016
Mirdametinib (PD-0325901) oral capsule or dispersible tablet
1
1
2019
Medication Event Monitoring System (MEMS)
1
1
2018
Binimetinib
1
1
2017
Turalio
1
1
2015

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 29th, 2021

Last Reviewed: November 30th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Curry BP, Alvarez R, Widemann BC, Johnson M, Agarwal PK, Lehky T, Valera V, Chittiboina P. Robotic Nerve Sheath Tumor Resection With Intraoperative Neuromonitoring: Case Series and Systematic Review. Oper Neurosurg (Hagerstown). 2022 Feb 1;22(2):44-50. doi: 10.1227/ONS.0000000000000051. https://pubmed.ncbi.nlm.nih.gov/350072702 Curry BP, Alvarez R, Widemann BC, Johnson M, Agarwal PK, Lehky T, Valera V, Chittiboina P. Robotic Nerve Sheath Tumor Resection With Intraoperative Neuromonitoring: Case Series and Systematic Review. Oper Neurosurg (Hagerstown). 2021 Dec 22. doi: 10.1227/ONS.0000000000000051. [Epub ahead of print] https://pubmed.ncbi.nlm.nih.gov/350072703 Curry BP, Alvarez R, Widemann BC, Johnson M, Agarwal PK, Lehky T, Valera V, Chittiboina P. Robotic Nerve Sheath Tumor Resection With Intraoperative Neuromonitoring: Case Series and Systematic Review. Oper Neurosurg (Hagerstown). 2022 Feb 1;22(2):44-50. doi: 10.1227/ONS.0000000000000051. Review. https://pubmed.ncbi.nlm.nih.gov/350072704 Prada CE, Jousma E, Rizvi TA, Wu J, Dunn RS, Mayes DA, Cancelas JA, Dombi E, Kim MO, West BL, Bollag G, Ratner N. Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol. 2013 Jan;125(1):159-68. doi: 10.1007/s00401-012-1056-7. Epub 2012 Oct 26. https://pubmed.ncbi.nlm.nih.gov/230998915 Babovic-Vuksanovic D, Widemann BC, Dombi E, Gillespie A, Wolters PL, Toledo-Tamula MA, O'Neill BP, Fox E, MacDonald T, Beck H, Packer RJ. Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas. Pediatr Neurol. 2007 May;36(5):293-300. https://pubmed.ncbi.nlm.nih.gov/175094606 Widemann BC, Arceci RJ, Jayaprakash N, Fox E, Zannikos P, Goodspeed W, Goodwin A, Wright JJ, Blaney SM, Adamson PC, Balis FM. Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Feb;56(2):226-33. doi: 10.1002/pbc.22775. Epub 2010 Sep 21. https://pubmed.ncbi.nlm.nih.gov/208600387 Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D, Gillespie A, Whitcomb P, Palumbo JS, Pitney A, Jayaprakash N, Zannikos P, Balis FM. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol. 2006 Jan 20;24(3):507-16. https://pubmed.ncbi.nlm.nih.gov/164214288 Wu J, Williams JP, Rizvi TA, Kordich JJ, Witte D, Meijer D, Stemmer-Rachamimov AO, Cancelas JA, Ratner N. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell. 2008 Feb;13(2):105-16. doi: 10.1016/j.ccr.2007.12.027. https://pubmed.ncbi.nlm.nih.gov/182425119 Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943. https://pubmed.ncbi.nlm.nih.gov/2802991810 Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Hardiman Dudley A, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest. 2013 Jan;123(1):340-7. doi: 10.1172/JCI60578. Epub 2012 Dec 10. https://pubmed.ncbi.nlm.nih.gov/23221341